Madrigal

Madrigal Pharmaceuticals (MDGL)

Company Description

Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease.

COMPANY ADDRESS
200 Barr Harbor Drive, Suite 400
West Conshohocken, PA 19428
United States

COMPANY EMAIL
info@madrigalpharma.com

COMPANY WEBSITE



Get BioInvest's perspective on Madrigal Pharmaceutical's CEO


Latest Company News

Madrigal Pharmaceuticals Inc (MDGL) Seeing Increased Volatility in Session Morgan Research - 11 hours ago Madrigal Pharmaceuticals Inc (MDGL) shares are moving today on volatility 3.10% or $0.53 from the open. The NASDAQ listed company saw a recent bid of 17.64 and 6349 shares have traded hands in the session. EPS for Fresenius SE (FSNUY) Expected At $0.00; Madrigal Pharmaceuticals (MDGL ... - Wolcott Daily [...]
Thu, Apr 27, 2017 6:45:00 PM, Continue reading at the source
Price Alert: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) Stock Nears Resistance ... CML News - Apr 19, 2017 Price Alert: Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) has now crossed into technical strength -- watch the technical oscillators for momentum gaps. [...]
Wed, Apr 19, 2017 11:36:00 AM, Continue reading at the source
Madrigal Pharmaceuticals Reports 2016 Fourth Quarter and Year-End Financial ... GlobeNewswire (press release) - Apr 3, 2017 CONSHOHOCKEN, Pa., April 03, 2017 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) today announced its fourth quarter and year-end 2016 financial results. MADRIGAL PHARMACEUTICALS,INC. (NASDAQ:MDGL) Files An 8-K Results of Operations ... - Market Exclusive [...]
Mon, Apr 03, 2017 11:26:00 AM, Continue reading at the source
Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL ... GlobeNewswire (press release) - Oct 20, 2016 CONSHOHOCKEN, Pa., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL) today announced that the first patient has been dosed in its Phase 2 study of MGL-3196 for the treatment of non-alcoholic steatohepatitis (NASH). [...]
Thu, Oct 20, 2016 11:36:00 AM, Continue reading at the source
Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License ... GlobeNewswire (press release) - Sep 19, 2016 CONSHOHOCKEN, Pa. and WATERTOWN, Mass., Sept. 19, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the ... With $163M Deal, Tarveda Revives Synta Pharma's Cancer Drug Work - Xconomy [...]
Mon, Sep 19, 2016 11:31:00 AM, Continue reading at the source
Synta - Madrigal Merger: Is There A Potential Value Play Here? Seeking Alpha - Aug 23, 2016 On April 13, 2016 Synta and Madrigal Pharmaceuticals (NASDAQ:MDGL) entered into an arrangement and plan of merger pursuant to which Saffron Merger Sub Inc., a wholly owned subsidiary of Synta, will merge into MDGL, with Madrigal surviving as the ... [...]
Tue, Aug 23, 2016 11:48:00 PM, Continue reading at the source
17.11 MarketWatch - Jul 25, 2016 Madrigal Pharmaceuticals Inc. Watchlist CreateMDGLAlert. After Hours. Last Updated: Apr 26, 2017 5:00 p.m. EDT. $ 17.11. 0.00 0.00%. After Hours Volume: 2. Close, Chg, Chg %. $17.11, -0.19, -1.10%. Created with Highstock 2.1.8 After-Hours 10am 12pm ... [...]
Mon, Jul 25, 2016 8:03:00 PM, Continue reading at the source
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading ... GlobeNewswire (press release) - Jul 22, 2016 FORT WASHINGTON, Pa., July 22, 2016 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the ... [...]
Fri, Jul 22, 2016 3:31:00 PM, Continue reading at the source
Synta Stock Up on Merger Deal with Madrigal Pharmaceuticals Zacks.com - Apr 15, 2016 This all-stock transaction will lead to the formation of a new company named Madrigal Pharmaceuticals, which will focus on the development of novel small-molecule drugs addressing major unmet needs related to cardiovascular-metabolic diseases and ... Synta Pharma and Madrigal Pharma to merge in all-stock deal - Seeking Alpha Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular ... - Business Wire (press release) [...]
Fri, Apr 15, 2016 2:47:00 PM, Continue reading at the source
Here's Why I'm Betting On Synta Pharmaceuticals Seeking Alpha - Jul 8, 2015 The company is approaching the first interim analysis of its Phase 3 GALAXY-2 trial of ganetespib in second-line non-small-cell lung carcinoma, which, if positive, should unlock considerable shareholder value. [...]
Wed, Jul 08, 2015 12:45:00 PM, Continue reading at the source